Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Share-based Compensation (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Share-based Compensation for 11 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 14.96% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.5 million, a 59.85% increase, with the full-year FY2025 number at $10.5 million, up 59.85% from a year prior.
  • Share-based Compensation was $2.1 million for Q4 2025 at Cartesian Therapeutics, down from $2.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $14.1 million in Q4 2023 to a low of $1.4 million in Q1 2024.
  • A 5-year average of $2.9 million and a median of $2.3 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 521.44% in 2023, then plummeted 86.81% in 2024.
  • Cartesian Therapeutics' Share-based Compensation stood at $2.3 million in 2021, then grew by 1.02% to $2.3 million in 2022, then soared by 521.44% to $14.1 million in 2023, then tumbled by 86.81% to $1.9 million in 2024, then increased by 14.96% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Share-based Compensation are $2.1 million (Q4 2025), $2.6 million (Q3 2025), and $3.3 million (Q2 2025).